EUVIMEDEUVIMED entdecken
EditorialKommentarOpen Access · CC BY 4.0

Proton-pump inhibitor use in combination with a CDK4/6 inhibitor: is formulation the issue?

Calum Polwart iD

The Oncologist · 06.08.2026 · 31 (9)

DOI: 10.1093/oncolo/oyag293 ↗

Kurz gefasst

Editorial in der Zeitschrift The Oncologist, online erschienen am 31.07.2026. Verfasst von Calum Polwart. Beteiligte Einrichtung: South Tees Hospitals NHS Foundation Trust, James Cook Cancer Institute, Middlesborough TS4 3BW, United Kingdom. Die Arbeit nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • South Tees Hospitals NHS Foundation Trust, James Cook Cancer Institute, Middlesborough TS4 3BW, United Kingdom.

ORCID-Profile: Calum Polwart

Zitieren

APA

Polwart, C. (2026). Proton-pump inhibitor use in combination with a CDK4/6 inhibitor: is formulation the issue?. The Oncologist, 31(9). https://doi.org/10.1093/oncolo/oyag293

Vancouver

Polwart C. Proton-pump inhibitor use in combination with a CDK4/6 inhibitor: is formulation the issue?. The Oncologist. 2026;31(9). doi:10.1093/oncolo/oyag293

BibTeX
@article{Polwart2026,
  author = {Polwart, Calum},
  title = {Proton-pump inhibitor use in combination with a CDK4/6 inhibitor: is formulation the issue?},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {9},
  doi = {10.1093/oncolo/oyag293}
}
Kostenlos starten →